The present invention provides a rapid, sensitive method for forensic drug testing in a post-mortem subject using oral fluid collected from the post-mortem subject. The method comprises collecting a sample of oral fluid from a post-mortem subject, analyzing the oral fluid sample qualitatively to detect the presence of one or more non-naturally occurring drugs, analyzing the oral fluid sample quantitatively to determine concentration of the one or more non-naturally occurring drugs in the post-mortem subject, and identifying the one or more non-naturally occurring drugs in the post-mortem subject. The detection and quantification in oral fluid is more sensitive and faster than detection and quantification of the non-naturally occurring drugs in blood, urine, bile, and liver tissue collected from the same post-mortem subject. Further, the qualitative and quantitative results are obtained in as little as three hours.

Disclosed herein are methods, compositions and systems for analyzing and detecting enzyme activity. For examples, methods, compositions and systems for parallel detection and analysis of enzymatic activities of enzymes in complex biological mixtures are provided.

The invention relates to detection the presence of a target molecule in a sample, wherein the sample is contacted with a substrate, the substrate subsequently being washed in a wash step. In particular, the invention relates to a method of detecting the presence of a target molecule in a sample, the method comprising: (a) contacting the sample (37) with a substrate having immobilized thereon probe molecules that specifically binds to the target molecule; (b) washing the substrate (38) in a wash step by a wash fluid in order to remove or dilute unbound target molecules; (c) detect the presence of resultant binding complexes (39) on the substrate to determine whether the target molecule is present in the sample. The wash fluid being substantially refractive index matched to the substrate.

The invention relates to detection the presence of a target molecule in a sample, wherein the sample is contacted with a substrate, the substrate subsequently being washed in a wash step. In particular, the invention relates to a method of detecting the presence of a target molecule in a sample, the method comprising: (a) contacting the sample (37) with a substrate having immobilized thereon probe molecules that specifically binds to the target molecule; (b) washing the substrate (38) in a wash step by a wash fluid in order to remove or dilute unbound target molecules; (c) detect the presence of resultant binding complexes (39) on the substrate to determine whether the target molecule is present in the sample. The wash fluid being substantially refractive index matched to the substrate.

The invention relates to a method for identifying one or more polymorphisms in nucleic acid samples, comprising: (a) performing a reproducible complexity reduction on a plurality of nucleic acid samples to provide a plurality of libraries of the nucleic acid samples comprising amplified fragments, wherein the reproducible complexity reduction comprises amplifying fragments of the nucleic acid samples using one or more primers to obtain the amplified fragments, and wherein the amplified fragments in each library comprise a unique identifier sequence to indicate origin of each library obtained by the reproducible complexity reduction; (b) combining the plurality of libraries to obtain a combined library and sequencing at least a portion of the combined library to obtain sequences; (c) aligning the sequences to obtain an alignment; and (d) identifying one or more polymorphisms in the plurality of nucleic acid samples.

Embodiments herein describe systems and methods to determine nucleic acid thermodynamics and uses thereof. Many embodiments utilize a sequencing chip, such as an Illumina flow cell as a high-throughput platform for performing massively parallel melt curve determination. In many embodiments, nucleic acid molecules possessing a region that forms a secondary structure are affixed to a sequencing chip and hybridized with one or more labeled oligonucleotides. As the secondary structure denatures, changes in fluorescence can be measured to determine a melt curve of specific sequences.

A method of analysing a sample mass spectrum comprises comparing a sample mass spectrum of a sample with each reference mass spectrum of plural reference mass spectra. A similarity index is assigned to each reference mass spectrum of the plural reference mass spectra based on similarity between the sample mass spectrum and the reference mass spectrum. For each group of one or more groups of the plural reference mass spectra, the similarity indexes for the reference mass spectra belonging to the group are combined so as to provide a group index for the group at a first level of a hierarchy of sample characteristics. The reference mass spectra belonging to each group are mass spectra of reference samples that have a particular characteristic in common. The method provides a way to categorise a sample as belonging to a particular group of reference samples.

A method of analysing a sample mass spectrum comprises comparing a sample mass spectrum of a sample with each reference mass spectrum of plural reference mass spectra. A similarity index is assigned to each reference mass spectrum of the plural reference mass spectra based on similarity between the sample mass spectrum and the reference mass spectrum. For each group of one or more groups of the plural reference mass spectra, the similarity indexes for the reference mass spectra belonging to the group are combined so as to provide a group index for the group at a first level of a hierarchy of sample characteristics. The reference mass spectra belonging to each group are mass spectra of reference samples that have a particular characteristic in common. The method provides a way to categorise a sample as belonging to a particular group of reference samples.

The present inventions relate to methods of preparing highly concentrated monoclonal antibody (mAb) formulations, including screening and selection of excipients to include in mAb formulation. Excipients include amino acids, salts and polyols.

The present inventions relate to methods of preparing highly concentrated monoclonal antibody (mAb) formulations, including screening and selection of excipients to include in mAb formulation. Excipients include amino acids, salts and polyols.